ABT241213C114000
- 0.30
- -0.71-70.30%
Abbott Laboratories Newsroom
Nephron Adjusts Price Target on Abbott Laboratories to $120 From $118
Oppenheimer Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Oppenheimer Sticks to Its Buy Rating for Abbott Laboratories (ABT)
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Sticks to Their Buy Rating for Abbott Laboratories (ABT)
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Strategic Initiatives and Innovations Drive Buy Rating for Abbott Laboratories
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
Wells Fargo Sticks to Its Buy Rating for Abbott Laboratories (ABT)
Abbott Laboratories Analyst Ratings
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $149
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $149
Barclays Adjusts Abbott Laboratories Price Target to $149 From $143
Oppenheimer Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130